This report was recently updated on December 19 2024 with the latest and most recent
market numbers
Global Head and Neck Cancer Therapeutics Market Size, Trends, and Analysis - Forecasts To 2026 By Therapeutic Class (PD Inhibitors, EGFR Inhibitors, and Microtubule Inhibitors), By Region (North America, Asia Pacific, CSA, Europe, and the Middle East and Africa); End-User Landscape, Company Market Share Analysis & Competitor Analysis
The growth of the head & neck cancer therapeutics market is driven due to the advancement of new & cost-effective therapies, various side effects associated with radiation therapy & chemotherapy, growing healthcare expenditure, and improved government policies are estimated to propel the market forward throughout the forecast period. There are a lot of medications for treating head & neck cancer, that could be used alone or in conjunction. For advanced-stage head & neck tumors, targeted immune therapy has become a popular treatment option, whereas traditional chemotherapeutic treatments are best used in conjunction with radiation therapy. These trends are all primarily driving the market for treatments for head & neck cancer to develop.
An increasing number of cases of head and neck cancer across geographic regions, increased demand for a combination treatment for head and neck cancer care, and increased research and development initiatives to determine the best clinical therapy all contribute to increased demand in the global market for head and neck cancer treatments. Besides that, a surge in the occurrence of risk factors, like alcohol, cigarette smoking, & tobacco use, is expected to fuel the rise in global demand for head & neck cancer therapies.
The high costs correlated with the treatment plan, the adverse reactions of alternative treatment options, the scarcity of insurance services, and the insufficient healthcare system in low- and middle-income nations are all expected to stymie market development. Furthermore, due to the debilitating impact of the standard of care healthcare methodologies, this patient demographic faces serious problems such as morbidity and low quality of life.
The latest patterns show that the global aging demographic, a hike in the reports of target illnesses, and the provision of better healthcare facilities as a result of government and private sector programs would propel the overall demand. The increased use of immunotherapy in many countries around the world presents an incentive for players to build on and grow widely in several areas, thus, boosting the global market of head and neck cancer therapeutics market.
Based on the therapeutic class, the market can be divided into PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors. The PD inhibitors segment holds the largest market share of the head & neck cancer therapeutics market. Novel product line launches are estimated to accelerate substantial growth in the PD inhibitor class of drugs throughout the forecast period. In patients with mature head and neck squamous cell carcinoma, novel PD inhibitors demonstrated increasingly effective therapeutic benefits and reduced toxicity as compared to standard therapies. Its major focus is on providing effective potential therapeutic options for patients with chronic or metastases head and neck squamous cell carcinoma.
Therapeutics with PD-1 inhibitors — Both nivolumab and pembrolizumab activate regulated death protein 1 (PD-1) and have shown significant functional efficacy in patients with head and neck squamous cell carcinoma; Both have been authorized by the US Food and Drug Administration (FDA) for patients who have subsequently received platinum-based chemotherapy for metastases or chronic head and neck squamous cell carcinoma. Thus, these aforementioned factors are responsible for the supremacy of the PD inhibitors segment.
As per the geographical analysis, the market can be classified into North America (the United States, Canada, and Mexico), Asia Pacific (India, China, Japan, Malaysia, Singapore, and Rest of Asia Pacific), Europe (Germany, United Kingdom, Italy, France, Spain, Netherlands, and Rest of Europe), Middle East & Africa (Saudi Arabia, United Arab Emirates, and Rest of the Middle East & Africa) and Central & South America (Brazil, Argentina, and Rest of Central and South America). North America is estimated to account for the major share of the head & neck cancer therapeutics market. Owing to the surging volume of core patient demographic, growing incidence of head & neck cancer, well-developed technologies, rising healthcare spending, and the existence of prominent leaders of the market, the expansion of the head & neck cancer drugs/therapeutics market has expanded steadily during the last few years. Because of its vast population pool, the prevalence of head and neck cancer, and increased demand for head and neck cancer hybrid therapeutics, Asia-Pacific offers attractive development prospects for leading players in the head and neck cancer drugs market. Threat indicators such as increased alcohol intake, increased cigarette smoking, and increased tobacco use are also projected to accelerate demand growth. In the Asia-Pacific zone, betel quid chewing is the most prevalent type of tobacco chewing. Besides that, a rise in disease consciousness and early detection, as well as an expansion in healthcare spending, drive the growth of the market in this area.
AstraZeneca Plc., Boston Biomedical, Inc., Astellas Pharma Inc., Acceleron Pharma, Inc., AB Science SA, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd. (Genentech, Inc.,), Eli Lilly and Company, Fresenius Medical Care AG & Co., Merck KGaA, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Ltd., Pfizer Inc., Bayer AG, AbbVie Inc., Sanofi S.A., and others are key players of head and neck cancer therapeutics market.
Please note: This is not an exhaustive list of companies profiled in the report.
Chapter 1 Methodology
1.1 Market Scope & Definitions
1.2 Estimates & Forecast Calculation
1.3 Historical Data Overview And Validation
1.4 Data Sources
1.4.1 Secondary
1.4.2 Primary
Chapter 2 Report Outlook
2.1 Global Head and Neck Cancer Therapeutics Industry Overview, 2016-2026
2.1.1 Industry Overview
2.1.2 Therapeutics Class Overview
2.1.3 Regional Overview
Chapter 3 Global Head and Neck Cancer Therapeutics Market Trends
3.1 Market Segmentation
3.2 Industry Background, 2016-2026
3.3 Market Key Trends
3.3.1 Positive Trends
3.3.1.1 Growing Healthcare Spending
3.3.1.2 Increasing Research Funding in Oncology
3.3.2 Industry Challenges
3.3.2.1 Side Effects of Available Treatment Options
3.4 Prospective Growth Scenario
3.4.1 Therapeutics Class Growth Scenario
3.5 COVID-19 Influence over Industry Growth
3.6 Porter’s Analysis
3.7 PESTEL Analysis
3.8 Value Chain & Supply Chain Analysis
3.9 Regulatory Framework
3.9.1 North America
3.9.2 Europe
3.9.3 APAC
3.9.4 LATAM
3.9.5 MEA
3.10 Technology Overview
3.11 Market Share Analysis, 2020
3.11.1 Company Positioning Overview, 2020
Chapter 4 Global Head and Neck Cancer Therapeutics Market, By Therapeutics Class
4.1 Therapeutics Class Outlook
4.2 PD Inhibitors
4.2.1 Market Size, By Region, 2016-2026 (USD Million)
4.3 EGFR Inhibitors
4.3.1 Market Size, By Region, 2016-2026 (USD Million)
4.4 Microtubule Inhibitors
4.4.1 Market Size, By Region, 2016-2026 (USD Million)
Chapter 5 Global Head and Neck Cancer Therapeutics Market, By Region
5.1 Regional outlook
5.2 North America
5.2.1 Market Size, By Country 2016-2026 (USD Million)
5.2.2 Market Size, By Therapeutics Class, 2016-2026 (USD Million)
5.2.3 U.S.
5.2.3.1 Market Size, By Therapeutics Class, 2016-2026 (USD Million)
5.2.4 Canada
5.2.4.1 Market Size, By Therapeutics Class, 2016-2026 (USD Million)
5.3 Europe
5.3.1 Market Size, By Country 2016-2026 (USD Million)
5.3.2 Market Size, By Therapeutics Class, 2016-2026 (USD Million)
5.3.3 Germany
5.2.3.1 Market Size, By Therapeutics Class, 2016-2026 (USD Million)
5.3.4 UK
5.3.4.1 Market Size, By Therapeutics Class, 2016-2026 (USD Million)
5.3.5 France
5.3.5.1 Market Size, By Therapeutics Class, 2016-2026 (USD Million)
5.3.6 Italy
5.3.6.1 Market Size, By Therapeutics Class, 2016-2026 (USD Million)
5.3.7 Spain
5.3.7.1 Market Size, By Therapeutics Class, 2016-2026 (USD Million)
5.3.8 Russia
5.3.8.1 Market Size, By Therapeutics Class, 2016-2026 (USD Million)
5.4 Asia Pacific
5.4.1 Market Size, By Country 2016-2026 (USD Million)
5.4.2 Market Size, By Therapeutics Class, 2016-2026 (USD Million)
5.4.3 China
5.4.3.1 Market Size, By Therapeutics Class, 2016-2026 (USD Million)
5.4.4 India
5.4.4.1 Market Size, By Therapeutics Class, 2016-2026 (USD Million)
5.4.5 Japan
5.4.5.1 Market Size, By Therapeutics Class, 2016-2026 (USD Million)
5.4.6 Australia
5.4.6.1 Market Size, By Therapeutics Class, 2016-2026 (USD Million)
5.4.7 South Korea
5.4.7.1 Market Size, By Therapeutics Class, 2016-2026 (USD Million)
5.5 Latin America
5.5.1 Market Size, By Country 2016-2026 (USD Million)
5.5.2 Market Size, By Therapeutics Class, 2016-2026 (USD Million)
5.5.3 Brazil
5.5.3.1 Market Size, By Therapeutics Class, 2016-2026 (USD Million)
5.5.4 Mexico
5.5.4.1 Market Size, By Therapeutics Class, 2016-2026 (USD Million)
5.5.5 Argentina
5.5.5.1 Market Size, By Therapeutics Class, 2016-2026 (USD Million)
5.6 MEA
5.6.1 Market Size, By Country 2016-2026 (USD Million)
5.6.2 Market Size, By Therapeutics Class, 2016-2026 (USD Million)
5.6.3 Saudi Arabia
5.6.3.1 Market Size, By Therapeutics Class, 2016-2026 (USD Million)
5.6.4 UAE
5.6.4.1 Market Size, By Therapeutics Class, 2016-2026 (USD Million)
5.6.5 South Africa
5.6.5.1 Market Size, By Therapeutics Class, 2016-2026 (USD Million)
Chapter 6 Company Landscape
6.1 Competitive Analysis, 2020
6.2 AstraZeneca Plc.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Strategic Positioning
6.2.4 Info Graphic Analysis
6.3 Boston Biomedical, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Strategic Positioning
6.3.4 Info Graphic Analysis
6.4 Astellas Pharma Inc.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Strategic Positioning
6.4.4 Info Graphic Analysis
6.5 Acceleron Pharma, Inc.
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Strategic Positioning
6.5.4 Info Graphic Analysis
6.6 AB Science SA
6.6.2 Financial Analysis
6.6.3 Strategic Positioning
6.6.4 Info Graphic Analysis
6.7 Bristol-Myers Squibb Company
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Strategic Positioning
6.7.4 Info Graphic Analysis
6.8 F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Strategic Positioning
6.8.4 Info Graphic Analysis
6.9 Eli Lilly and Company
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Strategic Positioning
6.9.4 Info Graphic Analysis
6.10 Fresenius Medical Care AG & Co.
6.10.2 Financial Analysis
6.10.3 Strategic Positioning
6.10.4 Info Graphic Analysis
6.11 Merck KGaA
6.11.1 Company Overview
6.11.2 Financial Analysis
6.11.3 Strategic Positioning
6.11.4 Info Graphic Analysis
6.12 PENTAX Medical
6.12.1 Company Overview
6.12.2 Financial Analysis
6.12.3 Strategic Positioning
6.12.4 Info Graphic Analysis
6.13 Teva Pharmaceutical Industries Limited
6.13.1 Company Overview
6.13.2 Financial Analysis
6.13.3 Strategic Positioning
6.13.4 Info Graphic Analysis
6.14 Sun Pharmaceutical Industries Ltd.
6.14.1 Company Overview
6.14.2 Financial Analysis
6.14.3 Strategic Positioning
6.14.4 Info Graphic Analysis
6.15 Pfizer Inc.
6.15.1 Company Overview
6.15.2 Financial Analysis
6.15.3 Strategic Positioning
6.15.4 Info Graphic Analysis
6.16 Bayer AG
6.16.1 Company Overview
6.16.2 Financial Analysis
6.16.3 Strategic Positioning
6.16.4 Info Graphic Analysis
6.17 AbbVie Inc.
6.17.1 Company Overview
6.17.2 Financial Analysis
6.17.3 Strategic Positioning
6.17.4 Info Graphic Analysis
6.18 Sanofi S.A.
6.18.1 Company Overview
6.18.2 Financial Analysis
6.18.3 Strategic Positioning
6.18.4 Info Graphic Analysis
6.19 Other Companies
6.19.1 Company Overview
6.19.2 Financial Analysis
6.19.3 Strategic Positioning
6.19.4 Info Graphic Analysis
The Global Head and Neck Cancer Therapeutics Market has been studied from the year 2019 till 2026. However, the CAGR provided in the report is from the year 2021 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Head and Neck Cancer Therapeutics Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
Or view our licence options:
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS
